Equity Method Accounting for Common Stock of OncoCyte, at Fair Value - Schedule of Condensed Results of Operations and Condensed Balance Sheet Information (Details) - OncoCyte Corporation [Member] - USD ($) $ in Thousands		2 Months Ended		12 Months Ended
		Feb. 16, 2017	[1]	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and development expense		$ 798		$ 7,174	$ 5,677	$ 4,527
General and administrative expense		377		9,232	4,265	3,867
Sales and marketing expense		213		2,443	1,198	324
Loss from operations		(1,388)		(18,849)	(11,140)	(8,718)
Net loss		$ (1,392)		(19,375)	(11,168)	$ (8,735)
Current assets	[2]			8,528	12,696
Noncurrent assets	[2]			1,688	1,751
Total assets	[2]			10,216	14,447
Current liabilities	[2]			4,454	4,275
Noncurrent liabilities	[2]			1,359	310
Stockholders' equity	[2]			4,403	9,862
Total liabilities and stockholders' equity	[2]			$ 10,216	$ 14,447

[1] OncoCyte’s condensed results of operations for the period from January 1, 2017 through February 16, 2017, the date immediately preceding the OncoCyte Deconsolidation, for the year ended December 31, 2017, and for the years ended December 31, 2016 and 2015, shown in the table below, are included in the consolidated results of operations of BioTime for those respective periods, after intercompany eliminations, as applicable.

[2] The condensed balance sheet information of OncoCyte as of December 31, 2017 and 2016, is provided for informational and comparative purposes only. OncoCyte was not included in BioTime’s consolidated balance sheet at December 31, 2017.